The RASopathies

Research output: Contribution to journalReview article

305 Citations (Scopus)

Abstract

The RASopathies are a clinically defined group of medical genetic syndromes caused by germline mutations in genes that encode components or regulators of the Ras/mitogen-activated protein kinase (MAPK) pathway. These disorders include neurofibromatosis type 1, Noonan syndrome, Noonan syndrome with multiple lentigines, capillary malformation-arteriovenous malformation syndrome, Costello syndrome, cardio-facio-cutaneous syndrome, and Legius syndrome. Because of the common underlying Ras/MAPK pathway dysregulation, the RASopathies exhibit numerous overlapping phenotypic features. The Ras/MAPK pathway plays an essential role in regulating the cell cycle and cellular growth, differentiation, and senescence, all of which are critical to normal development. Therefore, it is not surprising that Ras/MAPK pathway dysregulation has profound deleterious effects on both embryonic and later stages of development. The Ras/MAPK pathway has been well studied in cancer and is an attractive target for small-molecule inhibition to treat various malignancies. The use of these molecules to ameliorate developmental defects in the RASopathies is under consideration.

Original languageEnglish (US)
Pages (from-to)355-369
Number of pages15
JournalAnnual Review of Genomics and Human Genetics
Volume14
DOIs
StatePublished - Aug 2013
Externally publishedYes

Fingerprint

Mitogen-Activated Protein Kinases
Costello Syndrome
LEOPARD Syndrome
Gene Components
Neurofibromatosis 1
Germ-Line Mutation
Medical Genetics
Neoplasms
Cell Cycle
Growth

Keywords

  • Capillary malformation-arteriovenous malformation syndrome
  • Cardio-facio-cutaneous syndrome
  • Costello syndrome
  • Legius syndrome
  • LEOPARD syndrome
  • Neurofibromatosis
  • Noonan syndrome
  • Ras/MAPK
  • Signal transduction pathway

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics
  • Molecular Biology

Cite this

The RASopathies. / Rauen, Katherine A.

In: Annual Review of Genomics and Human Genetics, Vol. 14, 08.2013, p. 355-369.

Research output: Contribution to journalReview article

@article{2bcd56867508475fbbe33e9b7b00abb7,
title = "The RASopathies",
abstract = "The RASopathies are a clinically defined group of medical genetic syndromes caused by germline mutations in genes that encode components or regulators of the Ras/mitogen-activated protein kinase (MAPK) pathway. These disorders include neurofibromatosis type 1, Noonan syndrome, Noonan syndrome with multiple lentigines, capillary malformation-arteriovenous malformation syndrome, Costello syndrome, cardio-facio-cutaneous syndrome, and Legius syndrome. Because of the common underlying Ras/MAPK pathway dysregulation, the RASopathies exhibit numerous overlapping phenotypic features. The Ras/MAPK pathway plays an essential role in regulating the cell cycle and cellular growth, differentiation, and senescence, all of which are critical to normal development. Therefore, it is not surprising that Ras/MAPK pathway dysregulation has profound deleterious effects on both embryonic and later stages of development. The Ras/MAPK pathway has been well studied in cancer and is an attractive target for small-molecule inhibition to treat various malignancies. The use of these molecules to ameliorate developmental defects in the RASopathies is under consideration.",
keywords = "Capillary malformation-arteriovenous malformation syndrome, Cardio-facio-cutaneous syndrome, Costello syndrome, Legius syndrome, LEOPARD syndrome, Neurofibromatosis, Noonan syndrome, Ras/MAPK, Signal transduction pathway",
author = "Rauen, {Katherine A}",
year = "2013",
month = "8",
doi = "10.1146/annurev-genom-091212-153523",
language = "English (US)",
volume = "14",
pages = "355--369",
journal = "Annual Review of Genomics and Human Genetics",
issn = "1527-8204",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - The RASopathies

AU - Rauen, Katherine A

PY - 2013/8

Y1 - 2013/8

N2 - The RASopathies are a clinically defined group of medical genetic syndromes caused by germline mutations in genes that encode components or regulators of the Ras/mitogen-activated protein kinase (MAPK) pathway. These disorders include neurofibromatosis type 1, Noonan syndrome, Noonan syndrome with multiple lentigines, capillary malformation-arteriovenous malformation syndrome, Costello syndrome, cardio-facio-cutaneous syndrome, and Legius syndrome. Because of the common underlying Ras/MAPK pathway dysregulation, the RASopathies exhibit numerous overlapping phenotypic features. The Ras/MAPK pathway plays an essential role in regulating the cell cycle and cellular growth, differentiation, and senescence, all of which are critical to normal development. Therefore, it is not surprising that Ras/MAPK pathway dysregulation has profound deleterious effects on both embryonic and later stages of development. The Ras/MAPK pathway has been well studied in cancer and is an attractive target for small-molecule inhibition to treat various malignancies. The use of these molecules to ameliorate developmental defects in the RASopathies is under consideration.

AB - The RASopathies are a clinically defined group of medical genetic syndromes caused by germline mutations in genes that encode components or regulators of the Ras/mitogen-activated protein kinase (MAPK) pathway. These disorders include neurofibromatosis type 1, Noonan syndrome, Noonan syndrome with multiple lentigines, capillary malformation-arteriovenous malformation syndrome, Costello syndrome, cardio-facio-cutaneous syndrome, and Legius syndrome. Because of the common underlying Ras/MAPK pathway dysregulation, the RASopathies exhibit numerous overlapping phenotypic features. The Ras/MAPK pathway plays an essential role in regulating the cell cycle and cellular growth, differentiation, and senescence, all of which are critical to normal development. Therefore, it is not surprising that Ras/MAPK pathway dysregulation has profound deleterious effects on both embryonic and later stages of development. The Ras/MAPK pathway has been well studied in cancer and is an attractive target for small-molecule inhibition to treat various malignancies. The use of these molecules to ameliorate developmental defects in the RASopathies is under consideration.

KW - Capillary malformation-arteriovenous malformation syndrome

KW - Cardio-facio-cutaneous syndrome

KW - Costello syndrome

KW - Legius syndrome

KW - LEOPARD syndrome

KW - Neurofibromatosis

KW - Noonan syndrome

KW - Ras/MAPK

KW - Signal transduction pathway

UR - http://www.scopus.com/inward/record.url?scp=84884311848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884311848&partnerID=8YFLogxK

U2 - 10.1146/annurev-genom-091212-153523

DO - 10.1146/annurev-genom-091212-153523

M3 - Review article

C2 - 23875798

AN - SCOPUS:84884311848

VL - 14

SP - 355

EP - 369

JO - Annual Review of Genomics and Human Genetics

JF - Annual Review of Genomics and Human Genetics

SN - 1527-8204

ER -